WO2023053828A1

WO2023053828A1 - Chemotherapy control device, chemotherapy control system, method for controlling chemotherapy control device, and chemotherapy control program

Info

Publication number: WO2023053828A1
Application number: PCT/JP2022/032664
Authority: WO
Inventors: 伸一金田; 恵子大津
Original assignee: テルモ株式会社
Priority date: 2021-09-30
Filing date: 2022-08-30
Publication date: 2023-04-06

Abstract

A chemotherapy control device 10 controls at least a pump unit 14 for administering a drug and a heating unit 22 for heating a target site of a patient for hyperthermia therapy, and operates a peripheral tissue cooling unit 26 for cooling a peripheral tissue of the patient during an operation of the pump unit and heating unit.

Description

Chemotherapy control device, chemotherapy control system, control method of chemotherapy control device, and chemotherapy control program

The present invention relates to a chemotherapy control device, a chemotherapy control system, a control method of the chemotherapy control device, and a chemotherapy control program for controlling the administration of anticancer drugs.

Conventionally, in the treatment of cancer and the like, chemotherapy has been performed in which an anticancer drug is administered to a patient.
In addition, in chemotherapy, a proposal has been made to increase the therapeutic effect by heating a target tissue such as cancer (for example, Patent Document 1, etc.).

Japanese Patent Application Laid-Open No. 2001-314437

However, chemotherapy such as anticancer drug treatment may cause peripheral neuropathy in patients, which has become a problem.

Cooling of peripheral tissues is known to be a good preventive measure for peripheral neuropathy.
Therefore, in the present invention, a chemotherapy control device, a chemotherapy control system, and a chemotherapy control device that can suppress the occurrence of peripheral neuropathy in a patient by cooling peripheral tissues while enhancing the therapeutic effect of chemotherapy. The object is to provide a control method and a control program for a chemotherapy control device.

The object is, according to the present invention, to control at least a pump section that administers a drug and a heating section that heats a target site of a patient for hyperthermia treatment, and the operation of the pump section and the heating section. This is achieved by a chemotherapy control device characterized in that it is configured to operate a peripheral tissue cooling unit for cooling peripheral tissue of said patient.

According to the above configuration, the peripheral tissue cooling unit for cooling the patient's peripheral tissue, which is effective for suppressing the occurrence of peripheral neuropathy, is operated while the pump unit and the heating unit are in operation. Therefore, it is possible to prevent peripheral neuropathy or the like from occurring in a patient or the like when chemotherapy such as anticancer drug administration is performed.

Preferably, the chemotherapy control device has an extravasation symptom detection unit that detects an extravasation symptom of the drug administered to the patient, and the extravasation symptom detection unit detects the extravasation symptom. The operation of the pump unit is stopped when the operation is performed.

According to the above configuration, when the extravasation symptom detection unit detects the extravasation symptom, the operation of the pump unit is stopped, so the safety of the patient to whom the drug is administered is ensured.

Preferably, in the chemotherapy control device, the operation of the heating unit and the peripheral tissue cooling unit is not stopped immediately after the sign of extravasation is detected and the operation of the pump unit is stopped. It is characterized by

According to the above configuration, even after the operation of the pump unit is stopped, the operation of the heating unit and the peripheral tissue cooling unit is not stopped immediately, so that the promotion of the effect of chemotherapy by heating is immediately interrupted. There is no It is also possible to prevent the development of peripheral neuropathy or the like in patients.

Preferably, in the chemotherapy control apparatus, the pump unit receives information from a body temperature information measuring unit arranged at a site different from a site of the patient that is heated by the heating unit and cooled by the peripheral tissue cooling unit. The administration rate of the drug is controlled based on.

According to the above configuration, the administration rate of the drug is appropriately controlled based on the patient's body temperature and other conditions.
In addition, since the state of the patient's body temperature, etc., is different from that of the target site of the heating unit or the peripheral tissue cooling unit, it is possible to acquire accurate body temperature information of the patient or the like.

Preferably, the heating unit of the chemotherapy control device is configured to control heating based on body temperature information from a target tissue temperature measuring unit placed in the patient.

According to the above configuration, the heating unit controls the heating based on the body temperature information of the target tissue temperature measurement unit placed in the patient, so that the target site for treatment is set at a temperature effective for chemotherapy treatment. can do.
Moreover, even when the heating unit is affected by the cooling of the peripheral tissue cooling unit, it is possible to prevent the temperature of the heating unit from dropping more than necessary.

Preferably, the peripheral tissue cooling unit of the chemotherapy control device is configured to control the cooling temperature based on information from a peripheral tissue temperature measurement unit that acquires the temperature of the patient's peripheral tissue. and

According to the above configuration, the peripheral tissue cooling unit controls the cooling temperature based on the information from the peripheral tissue temperature measuring unit that acquires the body temperature of the patient's peripheral tissue. Prevent temperature to be properly controlled.
In addition, it is possible to prevent the temperature of the peripheral tissue cooling section from rising more than necessary due to the influence of the heating section.

The object is achieved, according to the present invention, by a pump unit for administering a drug, a heating unit for heating a target site of a patient for hyperthermia treatment, and a chemotherapy control unit for controlling the pump unit and the heating unit. wherein the chemotherapy control device is configured to operate a peripheral tissue cooling section for cooling peripheral tissue of the patient during operation of the pump section and the warming section. A chemotherapy control system characterized by:

The object is, according to the present invention, a control method for a chemotherapy control device for controlling at least a pump section for administering a drug and a heating section for heating a target site of a patient for hyperthermia treatment, comprising: This is achieved by a control method for a chemotherapy control apparatus, characterized in that a peripheral tissue cooling unit for cooling peripheral tissue of the patient is operated while the pump unit and the heating unit are in operation.

The object is achieved, according to the present invention, in a chemotherapy control device for controlling at least a pump section for administering a drug and a heating section for heating a target site of a patient for hyperthermia treatment. Accomplished by a chemotherapy control program for implementing the function of operating a peripheral tissue cooling unit that cools peripheral tissue of the patient during operation of the heating unit.

The present invention provides a chemotherapy control device, a chemotherapy control system, a control method for a chemotherapy control device, and a chemotherapy control that can suppress the occurrence of peripheral neuropathy in a patient while increasing the therapeutic effect of chemotherapy. Advantageously, a control program for the device can be provided.

1 is a schematic diagram showing the main configuration of, for example, an anticancer drug administration system 1, which is a chemotherapy control system. FIG. 2 is a schematic block diagram showing the main configuration of a main controller 10 of FIG. 1; FIG. 2 is a schematic flow chart showing an "anticancer drug administration step" of the present system 1; It is a schematic flowchart which shows a "heat treatment process." 2 is a schematic flow chart showing a "peripheral tissue cooling step"; 1 is a schematic flow chart showing a process for detecting extravasation of an anticancer drug during administration of the anticancer drug. 1 is a schematic diagram showing a peripheral tissue cooling device, (a) is a glove-type peripheral tissue cooling device 30 worn on a patient's hand, and (b) is a boot-type peripheral tissue cooling device 40 worn on a patient's foot. be. 1 is a schematic illustration of an "intravenous drip line" for administering an anticancer drug. FIG.

BEST MODE FOR CARRYING OUT THE INVENTION Preferred embodiments of the present invention will now be described in detail with reference to the accompanying drawings.
Since the embodiments described below are preferred specific examples of the present invention, they are subject to various technically preferable limitations. Unless otherwise stated, the invention is not limited to these modes.

(Main configuration of anticancer drug administration system 1)
FIG. 1 is a schematic diagram showing the main configuration of, for example, an anticancer drug administration system 1, which is a chemotherapy control system.
As shown in FIG. 1, the system 1 has, for example, a "main controller 10" which is a chemotherapy control device that controls the entire system.

The main controller 10, as shown in FIG. 1, is communicably connected to a "control electronic terminal 11" for the user to control the system 1. FIG.
In addition, the control electronic terminal 11 is connected to an "electronic medical record information storage unit 12" that stores various medical information of the patient (medical history, medication history of drugs such as anticancer drugs, vital data, etc.). there is
As shown in FIG. 1, the main controller 10 is configured to be able to access the "storage section (database) 13 for pharmacokinetic simulation information for each anticancer drug".
The electronic medical record information storage unit 12 and the pharmacokinetic simulation information storage unit 13 for each anticancer drug shown in FIG. 1 are stored in, for example, a "host computer" (not shown) or the like.

The pharmacokinetics simulation information storage unit 13 for each anticancer drug stores "medicamental pharmacokinetics simulation information" for each anticancer drug, that is, information on drug behavior in the body (transition into tissue, etc.) and the like.
In addition, the main controller 10 controls, for example, a smart pump 14, which is a pump unit for administering the anticancer drug to the patient.
Specifically, the smart pump 14 is an infusion pump or the like, and includes a so-called drug library (types of various drugs, various administration modes corresponding to various drugs, upper/lower limits of administration rates), and an upstream of the smart pump 14. Equipped with occlusion pressure detection sensors that detect the occlusion pressure of the tube on the side and downstream side, and the upper limit of occlusion pressure etc. are stored in the storage unit, and the administration of anticancer drugs is controlled safely and accurately. ing.

In addition, the main controller 10 controls the following devices and the like.
For example, the target tissue temperature measurement unit shown in FIG. "Vital sensors 23" for measuring respiratory rate, blood oxygen saturation, etc.), "Droplet sensor 24a" and "Micro pressure sensor 24b" arranged in the "intravenous drip line" for anticancer drugs to be described later. and "minute flow velocity sensor 24c".
In addition, the main controller 10 includes a body temperature information measuring unit such as an anticancer drug body temperature sensor 25, a peripheral tissue cooling unit such as a cooling pad 26, and a peripheral tissue body temperature measuring unit such as It is configured to also control the "skin temperature sensor 27" and the like.
Specifically, for example, the devices shown in FIG. 1, such as the skin temperature sensor 27, are communicably connected to the main controller 10 and the like by short-range wireless communication or the like. Note that this connection may be wired.
Details of these devices will be described later.

In addition, the main controller 10, control electronic terminal 11, smart pump 14, and other devices in FIG. Read Only Memory), etc., and these are connected via a bus or the like.

FIG. 2 is a schematic block diagram showing the main configuration of the main controller 10 of FIG. 1. As shown in FIG.
The contents of each block shown in FIG. 2 will be described later.

3 to 6 are schematic flow charts showing examples of main operations of the anticancer drug administration system 1 according to this embodiment.
An example in which the system 1 is used to administer an "anticancer agent" to a patient with stomach cancer, skin cancer, or the like will be described below in detail.

FIG. 3 is a schematic flow chart showing the "anticancer drug administration step" of the system 1. As shown in FIG.
Before the administration step in FIG. 3, the doctor in charge of the patient specifies the "patient ID" of the patient and the "anticancer drug" to be administered, and inputs them into the "electronic medical record information storage unit 12".
Next, the process proceeds to step (hereinafter referred to as "ST") 1 in FIG. In ST1, the "individualized administration control pattern generation processing unit (program) 101" of the main controller 10 in FIG. Based on the pharmacokinetic simulation information of the anticancer drug in the information storage unit 13, the "individualized administration control pattern" information of the patient is generated and stored in the "individualized administration control pattern storage unit 102" of FIG. .

That is, when a specific anticancer drug is administered to the patient, pattern information such as tissue migration of the anticancer drug to the target tissue (affected area) such as the stomach and skin is generated and stored.

Then proceed to ST2. In ST2, the "medicine administration processing unit (program) 103" of the main controller 10 operates, based on the "individualized administration control pattern", operates the "smart pump 14 (infusion pump, etc.)" of FIG. The pump 14 is caused to administer the anticancer drug.

Specifically, based on the "individualized administration control pattern", the "dosage" and "administration rate" of the anticancer drug are controlled so that they are within the optimal range.

Next, go to ST3. In ST3, the "medicine administration processing unit (program) 103" operates to acquire the "body temperature representative value as biological information" from the "anticancer drug body temperature sensor 25" in FIG.
The body temperature sensor 25 for the anticancer drug of the patient is placed at a "other site of the patient" different from the place where the "target tissue temperature measuring probe 21" and "cooling pad 26" described later are placed.
In this way, the "anti-cancer drug body temperature sensor 25" for grasping the state of the patient's body temperature, etc., measures the body temperature at a site different from the local heating pad 22 and the cooling pad 26, so that the patient's body temperature is more accurate. Information can be obtained.

In this way, the "drug administration processing unit (program) 103" considers the influence at regular intervals based on the "representative body temperature value as biological information" acquired from the "body temperature sensor for anticancer drug 25", Based on the in vivo pharmacokinetic simulation information 13 for each anticancer drug in FIG. 1, the administration rate control of anticancer drug administration is corrected.

Therefore, according to this embodiment, the administration rate of the anticancer drug is appropriately controlled based on the patient's body temperature and other conditions.

Then proceed to ST4 or ST5. In ST4, the "medicine administration processing unit (program) 103" operates to determine whether administration of the specified amount of the anticancer drug has been completed. and terminate anticancer drug administration.

In ST5, the "drug administration processing unit (program) 103" operates, and biological information (heart rate, blood pressure, body temperature, respiratory rate, blood oxygen saturation, etc.) and determines whether or not an abnormality has been detected. When an abnormality is detected, an alert is issued and the administration of the anticancer drug is suspended.

Specifically, it is determined whether or not the vital data and the like are within the standard, and if it is not within the standard, an emergency stop is made.
Thus, in this embodiment, patient safety is ensured when administering an anticancer drug.

FIG. 4 is a schematic flow chart showing the "heat treatment process".
The "thermal treatment process" of the anticancer drug will be described along FIG.
“Cancer thermotherapy (hyperthermia) is a treatment method that uses high-frequency energy to heat and destroy cancer tissue. It is expected to play an important role in therapeutic therapy.
For this reason, in the present embodiment, along with administration of an anticancer drug, a "thermal treatment" is performed by placing a "local heating pad 22" in FIG. 1 on a target site such as the stomach or skin.

The outer surface of the local heating pad 22 is covered with a heat insulating material such as a high-performance filling material or aluminum foil. It is a device that can raise the core body temperature without increasing the surface temperature as much as possible. are also located at positions corresponding to the target sites.
For example, when using the topical heating pad 22 for stomach cancer or skin cancer, the topical heating pad 22 is placed only on the skin portion corresponding to the target site, the stomach, and only on the target site for skin cancer.

In addition, in order to minimize the mutual interference between the hyperthermia treatment and the "peripheral tissue cooling method for reducing side effects of anticancer drug treatment (peripheral neuropathy)" described later, the local heating pad 22 is applied to the target tissue. It is preferable to use a device that can raise the temperature to a limited extent.

Further, in the present embodiment, the "target tissue temperature measuring probe 21" shown in FIG. It is configured to measure the target tissue temperature of the target tissue.

Then, the process proceeds to ST11 in FIG. In ST11, the "heat therapy processing unit (program) 104" in FIG. 2 operates to determine whether or not the "smart pump 14" is performing drug administration.
Then, when it is determined that it has been executed, the process proceeds to ST12. In ST12, the "thermal treatment processing unit 104" in FIG. 2 operates to monitor the "target tissue temperature" acquired from the target tissue temperature measuring probe 21, and the resulting feedback information is "within the prescribed range". or not.

Then, if it is out of the specified range, proceed to ST13. In ST13, the output (temperature) of the local heating pad 22, etc.) is controlled.

As described above, according to the present embodiment, by controlling the heating based on the body temperature information of the local heating pad 22 placed on the patient, it is possible to obtain an effective temperature for chemotherapy treatment.
In addition, even when the topical heating pad 22 is affected by the cooling of the cooling pad 26, it is possible to prevent the temperature of the topical heating pad 22 from dropping more than necessary.
In particular, when the cancer is superficial cancer such as skin cancer, the temperature control of the local heating pad 22 is extremely important because the cancer is easily affected by the cooling of the cooling pad 26 .

Next, go to ST14. In ST14, the "thermal treatment processing unit (program) 104" operates, and any of the biological information (heart rate, blood pressure, respiratory rate, body temperature, blood oxygen saturation, etc.) that is vital information acquired from the vital sensors 23 If an abnormality is detected, an alert is issued and the operation of the local heating pad 22 is temporarily stopped.
Specifically, it is determined whether or not the biometric information is within the preset criteria for the patient, and if it is not within the criteria, an emergency stop is made.

Thus, in this embodiment, patient safety is ensured during hyperthermia treatment.

FIG. 5 is a schematic flow chart showing the "peripheral tissue cooling step".
In the present embodiment, the purpose is to suppress the occurrence of peripheral neuropathy or the like in patients due to the administration of anticancer agents. Since it is configured to cool the patient's peripheral tissues, such as extremities, at the same time as administering the anticancer drug, a specific description will be given below.

FIG. 7 is a schematic diagram showing a peripheral tissue cooling device, (a) is a glove-type peripheral tissue cooling device 30 worn on the patient's hand, and (b) is a boot-shaped peripheral tissue cooling device worn on the patient's foot. A cooler 40 is provided.
As shown in FIG. 7, the glove type and the boot type each have a plurality of "cooling pads 26" for cooling the peripheral tissues of the hands and feet, and measure the skin temperature of the hands and feet. A skin temperature sensor 27 (such as a thermistor) is provided for this purpose.

The glove-type peripheral tissue cooling device 30 and the boot-type peripheral tissue cooling device 40 have built-in cooling pads 26 that can increase adhesion by pressurization in order to enhance the cooling effect on the skin.
When a Peltier element is used as the cooling means for the cooling pad 26, the side opposite to the cooling portion becomes a heating portion. , radiating holes, etc.) (not shown) may be provided at appropriate locations to dissipate heat to the outside air, but the heat dissipating means is not limited to this.
Furthermore, the cooling effect can be enhanced by covering the outer surfaces of the glove-type peripheral tissue cooling device 30 and the boot-type peripheral tissue cooling device 40 with a heat-insulating member such as high-performance batting material or aluminum foil.
Alternatively, a heat insulating member such as aluminum foil may be placed on the outermost surface of the glove-type peripheral tissue cooling device 30 or the boot-type peripheral tissue cooling device 40, and these may be used as radiators at the same time.
Especially in the hands and fingers, even when the administration site, which is the target site of anticancer drugs, and the cooling site overlap, the pressure is so light that it does not cause extravasation due to pressure and can ensure adhesion. is pressurized.

Next, the peripheral tissue cooling process will be described along FIG.
In ST21 of FIG. 5, the "peripheral tissue cooling processing unit (program) 105" of FIG. 2 operates, and the "smart pump 14" determines whether drug administration is being performed.
Then, if it is executed, the process proceeds to ST22. In ST22, the "peripheral tissue cooling processor (program) 105" operates, and cools the patient through the cooling pad 26 of the glove-type peripheral tissue cooler 30 or the boot-type peripheral tissue cooler 40 shown in FIG. Cools the peripheral tissues of the extremities.

Then proceed to ST23. In ST23, the "temperature" obtained from the skin temperature sensors 27 of the glove-type peripheral tissue cooling device 30 and the boot-type peripheral tissue cooling device 40 is monitored, and whether or not the resulting feedback information is "within a prescribed range". is determined, and if it is out of the specified range, the output (temperature) of the cooling pad 26 is adjusted and controlled within the specified range.

Specifically, in order to control peripheral neuropathy while preventing frost damage to the patient, the skin temperature is controlled to a cooling temperature within a specified range, for example, 10 to 16 degrees.
This control is executed for each glove-type peripheral tissue cooler 30 and boot-type peripheral tissue cooler 40 .

As described above, according to the present embodiment, the cooling pad 26 for cooling the patient's peripheral tissue is operated while the smart pump 14 and the local heating pad 22 are operating. At the time of administration, it is possible to prevent the development of peripheral neuropathy or the like in patients.

Also, it is possible to prevent the temperature of the cooling pad 26 from rising more than necessary due to the influence of the local heating pad 22 .

Then proceed to ST24. In ST24, the "peripheral tissue cooling processing unit (program) 105" operates, and an abnormality is detected in the biological information (heartbeat, blood pressure, respiratory rate, blood oxygen saturation, etc.) which is vital information acquired from the vital sensors 23. If so, it issues an alert and suspends operation of the cooling pad 26 at the same time.

Thus, in this embodiment, patient safety is ensured during peripheral tissue cooling.

FIG. 6 is a schematic flow chart showing steps for detecting extravasation of an anticancer drug during administration of the anticancer drug.
Also, FIG. 8 is a schematic illustration of an "intravenous infusion line" for administering an anticancer drug.
As shown in FIG. 8, the intravenous drip line serves as a drug administration circuit from a "drip tube 24d" containing an anticancer drug to an "administration needle 24e" for actually administering the anticancer drug to the patient. there is
Then, a "droplet sensor 24a" is attached to the drip tube 24d, an in-line "micro pressure sensor 24b" installed in the drug administration circuit, and a "microflow velocity sensor 24c" using an ultrasonic wave or a temperature sensor are installed. It has become.
These "droplet sensor 24a", "micro pressure sensor 24b", and "micro flow rate sensor 24c" function as an extravasation sign detector.

Next, the "extravasation detection step" will be described with reference to FIG.
First, go to ST31. In ST31, the extravasation symptom detection unit in FIG. 2, for example, the "extravasation detection processing unit (program) 106" operates to determine whether or not the "smart pump 14" is performing drug administration. .

Then, when it is determined that it is being performed, administration is performed based on the data from the extravasation sign detection units, which are the "droplet sensor 24a", the "micro pressure sensor 24b", and the "micro flow rate sensor 24c" in FIG. It determines whether there is a sign of extravasation by capturing changes in fluid flow rate and back pressure.
In this manner, since the presence or absence of signs of "extravasation" is determined by a plurality of sensors installed in the intravenous drip line, highly accurate determination is possible.

In this embodiment, signs of "extravasation" are determined from the sensor installed in the intravenous drip line, but the present invention is not limited to this.
For example, the target site of drug administration (stomach, skin, etc.) is intended to be protected so as not to hinder the movement of the administration needle 24e and catheter of the indwelling needle due to body movement and the influence of the cooling pad 26 (peripheral tissue cooling method). A protective pad is attached, and a temperature sensor may be incorporated in this protective pad to detect temperature changes at the administration site and use it for early detection of signs of extravasation.

Next, if there is a sign of extravasation, proceed to ST33. In ST33, administration of the anticancer drug is immediately stopped immediately, but cooling of the extremities (cooling pad 26) and thermal treatment of the target site (local heating pad 22) are stopped after a certain period of time (about 30 minutes). program to let

That is, the cooling or heating operation is performed for a certain period of time after the operation of the smart pump 14 is stopped, not immediately. Therefore, the effects of chemotherapy with anticancer agents are not lost immediately, and the occurrence of peripheral neuropathy and the like in patients is continuously suppressed.
As described above, according to the present embodiment, when a sign of extravasation is detected, the operation of the smart pump 14 is stopped, so that the safety of the patient during the administration of the anticancer drug can be ensured. Become.

In the present embodiment described above, the case where it is realized as a device has been described as an example, but the present invention is not limited to this, and the program that can be executed by a computer is a magnetic disk (floppy (registered (trademark) disk, hard disk, etc.), optical disk (CD-ROM, DVD, etc.), magneto-optical disk (MO), semiconductor memory, or other storage medium.

Also, the storage medium may be any computer-readable storage medium that can store the program. The storage format of the storage medium is not particularly limited.

In order to realize this embodiment, the OS (operating system) running on the computer based on the instructions of the program installed in the computer from the storage medium, MW (middleware) such as database management software, network software, etc. A part of each process may be executed, and the cloud may be used.

Furthermore, the storage medium in the present invention is not limited to a medium independent of a computer, and includes a storage medium in which a program transmitted via LAN, Internet, etc. is downloaded and stored or temporarily stored.

Further, the computer in the present invention may execute each process in the present embodiment based on a program stored in a storage medium, and may be a device consisting of a single personal computer (PC) or the like, or a plurality of devices. may be a system or the like connected to a network.

In addition, the computer in the present invention is not limited to a personal computer, but includes an arithmetic processing unit included in information processing equipment, a microcomputer, an arithmetic processing system on the cloud, etc., and can realize the function of the present invention by a program. equipment, devices, and systems.

The embodiment of the present invention has been described above. However, the present invention is not limited to the above embodiments, and various modifications can be made without departing from the scope of the claims.

Reference Signs List 1 anticancer drug administration system 10 main controller 11 control electronic terminal 12 electronic medical record information storage unit 13 pharmacokinetics simulation information for each anticancer drug Storage unit 14 Smart pump 21 Probe for measuring target tissue temperature 22 Local thermal pad 23 Vital sensors 24a Droplet sensor 24b Micro pressure sensor 24c Micro flow rate sensor

24d Infusion tube

24e Administration needle 25 Body temperature sensor for anticancer drug 26 Cooling pad 27 Skin temperature sensor 30 glove-type peripheral tissue cooling device 40 boot-type peripheral tissue cooling device 101 individualized administration control pattern generation processing unit 102 individualized administration control pattern storage unit 103... drug administration processing unit, 104... hyperthermia treatment processing unit, 105... peripheral tissue cooling processing unit, 106... extravasation detection processing unit

Claims

controlling at least a pump unit for administering a drug and a heating unit for heating a target site of a patient for hyperthermia treatment;
A chemotherapy control apparatus characterized by being configured to operate a peripheral tissue cooling unit for cooling the patient's peripheral tissue during operation of the pump unit and the heating unit.
an extravasation sign detection unit that detects signs of extravasation of the drug administered to the patient;
2. The chemotherapy control apparatus according to claim 1, wherein the operation of the pump unit is stopped when the extravasation symptom detecting unit detects the extravasation symptom.
3. The apparatus according to claim 2, wherein the operation of the heating unit and the peripheral tissue cooling unit is not stopped immediately after the sign of extravasation is detected and the operation of the pump unit is stopped. chemotherapy controller.
The pump unit controls the administration rate of the drug based on information from a body temperature information measuring unit arranged at a site different from a site of the patient heated by the heating unit and cooled by the peripheral tissue cooling unit. 4. The chemotherapy control device according to any one of claims 1 to 3, characterized in that
5. The heating unit according to any one of claims 1 to 4, wherein the heating unit is configured to control heating based on body temperature information from a target tissue temperature measuring unit placed on the patient. A chemotherapy control device as described in .
6. The peripheral tissue cooling unit is configured to control the cooling temperature based on information from a peripheral tissue temperature measuring unit that acquires the body temperature of the patient's peripheral tissue. A chemotherapy control device according to any one of the preceding claims.
a pump section for administering a drug;
a heating unit that heats a target site of a patient for hyperthermia treatment;
A chemotherapy control system comprising the pump unit and a chemotherapy control device that controls the heating unit,
A chemotherapy control system, wherein the chemotherapy control device is configured to operate a peripheral tissue cooling unit for cooling the peripheral tissue of the patient during operation of the pump unit and the heating unit.
A control method for a chemotherapy control device that controls at least a pump unit for administering a drug and a heating unit for heating a target site of a patient for hyperthermia treatment, comprising:
A control method for a chemotherapy control apparatus, wherein a peripheral tissue cooling unit for cooling peripheral tissue of the patient is operated while the pump unit and the heating unit are in operation.
a chemotherapy controller that controls at least a pump portion for administering drugs and a heating portion for heating a target site of a patient for hyperthermia treatment;
A chemotherapy control program for realizing a function of operating a peripheral tissue cooling unit that cools peripheral tissue of the patient during operation of the pump unit and the heating unit.